{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:57:44Z","timestamp":1781233064347,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05873-y","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:01:57Z","timestamp":1777370517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement in left ventricular ejection fraction and fluid compartment dynamics in patients with heart failure and type 2 diabetes treated with SGLT-2 inhibitors"],"prefix":"10.1186","volume":"26","author":[{"given":"Ye\u015fim \u00c7elik","family":"Kantar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"A\u00e7maz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Kantar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fclfiye","family":"Kuzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali \u0130hsan","family":"G\u00fcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"5873_CR1","doi-asserted-by":"publisher","first-page":"115734","DOI":"10.1016\/j.biopha.2023.115734","volume":"168","author":"SA Antar","year":"2023","unstructured":"Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetesmellitus: Classification, mediators, andcomplications; A gatetoidentifypotentialtargetsforthedevelopment of neweffectivetreatments. BiomedPharmacother. 2023;168:115734. https:\/\/doi.org\/10.1016\/j.biopha.2023.115734.","journal-title":"BiomedPharmacother"},{"issue":"2","key":"5873_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiologyandepidemiology of type 2 diabetesmellitusanditscomplications. NatRevEndocrinol. 2018;14(2):88\u201398. https:\/\/doi.org\/10.1038\/nrendo.2017.151.","journal-title":"NatRevEndocrinol"},{"issue":"Suppl","key":"5873_CR3","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.molmet.2019.06.016","volume":"27S","author":"M Laakso","year":"2019","unstructured":"Laakso M. Biomarkersfortype 2 diabetes. Mol Metab. 2019;27S(Suppl):S139\u201346. https:\/\/doi.org\/10.1016\/j.molmet.2019.06.016.","journal-title":"Mol Metab"},{"issue":"1","key":"5873_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","volume":"6","author":"M Arrigo","year":"2020","unstructured":"Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acuteheartfailure NatRevDisPrimers. 2020;6(1):16. https:\/\/doi.org\/10.1038\/s41572-020-0151-7.","journal-title":"Acuteheartfailure NatRevDisPrimers"},{"key":"5873_CR5","doi-asserted-by":"publisher","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","volume":"125","author":"SS Jankauskas","year":"2021","unstructured":"Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, et al. Heartfailure in diabetes. Metabolism. 2021;125:154910. https:\/\/doi.org\/10.1016\/j.metabol.2021.154910.","journal-title":"Metabolism"},{"issue":"6S","key":"5873_CR6","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.amjmed.2017.04.010","volume":"130","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N, DiabetesMellitusandHeartFailure. Am J Med. 2017;130(6S):S40\u201350. https:\/\/doi.org\/10.1016\/j.amjmed.2017.04.010.","journal-title":"Am J Med"},{"issue":"21","key":"5873_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patientswithheartfailureandreducedejectionfraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"3","key":"5873_CR8","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","volume":"325","author":"X Chen","year":"2023","unstructured":"Chen X, Hocher CF, Shen L, Kr\u00e4mer BK, Hocher B. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench. Am J Physiol Cell Physiol. 2023;325(3):C661\u201381. https:\/\/doi.org\/10.1152\/ajpcell.00177.2023. Epub 2023 Jul 31. PMID: 37519230.","journal-title":"Am J Physiol Cell Physiol"},{"key":"5873_CR9","doi-asserted-by":"publisher","first-page":"118497","DOI":"10.1016\/j.biopha.2025.118497","volume":"191","author":"X Chen","year":"2025","unstructured":"Chen X, Wohnhaas CT, Deli\u0107 D, Schommer N, Duerschmied D, Cao Y, Zhang Z, Reichetzeder C, Gaballa MMS, Kr\u00e4mer BK, Klein T, He B, Shen L, Hocher B. Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5\/6 nephrectomy. Biomed Pharmacother. 2025;191:118497. Epub 2025 Aug 28. PMID: 40882522.","journal-title":"Biomed Pharmacother"},{"key":"5873_CR10","doi-asserted-by":"publisher","first-page":"116650","DOI":"10.1016\/j.biopha.2024.116650","volume":"175","author":"R Madonna","year":"2024","unstructured":"Madonna R, Biondi F, Alberti M, Ghelardoni S, Mattii L, D\u2019Alleva A. Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review. Biomed Pharmacother. 2024;175:116650. https:\/\/doi.org\/10.1016\/j.biopha.2024.116650. Epub 2024 Apr 27. PMID: 38678962.","journal-title":"Biomed Pharmacother"},{"key":"5873_CR11","doi-asserted-by":"publisher","first-page":"147032032513646","DOI":"10.1177\/14703203251364668","volume":"26","author":"S Bah\u00e7eba\u015f\u0131","year":"2025","unstructured":"Bah\u00e7eba\u015f\u0131 S, et al. Differentialeffects of amlodipineandramipril on fluidcompartments, sodiumbalance, andedema in hypertensivepatients. J Renin AngiotensinAldosteroneSyst. 2025;26:14703203251364668. https:\/\/doi.org\/10.1177\/14703203251364668.","journal-title":"J Renin AngiotensinAldosteroneSyst"},{"issue":"Suppl 1","key":"5873_CR12","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"AmericanDiabetesAssociation Professional PracticeCommittee","year":"2025","unstructured":"AmericanDiabetesAssociation Professional PracticeCommittee. DiagnosisandClassification of Diabetes: Standards of Care in Diabetes\u20142025. DiabetesCare. 2025;48(Suppl 1):S27\u201349. https:\/\/doi.org\/10.2337\/dc25-S002.","journal-title":"DiabetesCare"},{"key":"5873_CR13","doi-asserted-by":"publisher","first-page":"176179","DOI":"10.1016\/j.ejphar.2023.176179","volume":"961","author":"AN Emara","year":"2023","unstructured":"Emara AN, Wadie M, Mansour NO, Shams MEE. Theclinicaloutcomes of dapagliflozin in patientswithacuteheartfailure. Eur J Pharmacol. 2023;961:176179. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176179.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"5873_CR14","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.18621\/eurj.1349473","volume":"9","author":"O Aslan","year":"2023","unstructured":"Aslan O, Demirci EE. Evaluation of theclinicalvalue of sodiumexamination in spot urine in patientspresentingwithacuteheartfailurewhileusing SGLT2i. Eur Res J. 2023;9(6):1454\u201363. https:\/\/doi.org\/10.18621\/eurj.1349473.","journal-title":"Eur Res J"},{"key":"5873_CR15","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.5114\/amsad.2022.116665","volume":"7","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Papadopoulos C, Karagiannis A, Doumas M. Sodium-glucose co-transporter-2 inhibitormediatedcardio-protection. ArchMedSciAtherosclerDis. 2022;7:e39\u201341. https:\/\/doi.org\/10.5114\/amsad.2022.116665.","journal-title":"ArchMedSciAtherosclerDis"},{"issue":"4","key":"5873_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.hfc.2022.03.005","volume":"18","author":"V Vallon","year":"2022","unstructured":"Vallon V. RenoprotectiveEffects of SGLT2 Inhibitors. Heart Fail Clin. 2022;18(4):539\u201349. https:\/\/doi.org\/10.1016\/j.hfc.2022.03.005.","journal-title":"Heart Fail Clin"},{"issue":"7","key":"5873_CR17","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, DiMartino A, Albanese G, et al. CardiorenalProtectiveMechanisms of SGLT2 Inhibitors. Int J Mol Sci. 2022;23(7):3651. https:\/\/doi.org\/10.3390\/ijms23073651.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5873_CR18","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3390\/biomedicines10082016","volume":"10","author":"RD Sullivan","year":"2022","unstructured":"Sullivan RD, McCune ME, Hernandez M, Reed GL, Gladysheva IP. Suppression of CardiogenicEdemawith SGLT-2 Inhibitors. Biomedicines. 2022;10(8):2016. https:\/\/doi.org\/10.3390\/biomedicines10082016.","journal-title":"Biomedicines"},{"issue":"10","key":"5873_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752\u201372. Epub 2016 Jul 28. PMID: 27470878.","journal-title":"Circulation"},{"issue":"6","key":"5873_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632\u201344. PMID: 32613148; PMCID: PMC7315190.","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"5873_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190. Epub 2020 Aug 28. PMID: 32865377.","journal-title":"N Engl J Med"},{"key":"5873_CR22","doi-asserted-by":"publisher","first-page":"e077097","DOI":"10.1136\/bmj-2023-077097","volume":"385","author":"P Bidulka","year":"2024","unstructured":"Bidulka P, Lugo-Palacios DG, Carroll O, O\u2019Neill S, Adler AI, Basu A, et al. Comparativeeffectiveness of secondline oral antidiabetictreatments. BMJ. 2024;385:e077097. https:\/\/doi.org\/10.1136\/bmj-2023-077097.","journal-title":"BMJ"},{"issue":"12","key":"5873_CR23","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3390\/medicina60122096","volume":"60","author":"JC De La Flor","year":"2024","unstructured":"De La Flor JC, CotoMorales B, Basabe E, Rey Hernandez M, ZamoraGonz\u00e1lez-Mari\u00f1o R, Rodr\u00edguezTudero C, et al. Effects of SGLT-2 Inhibitors on Body CompositionandFluidStatus. Med (Kaunas). 2024;60(12):2096. https:\/\/doi.org\/10.3390\/medicina60122096.","journal-title":"Med (Kaunas)"},{"issue":"11","key":"5873_CR24","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3346\/jkms.2017.32.11.1828","volume":"32","author":"EM Yang","year":"2017","unstructured":"Yang EM, Park E, Ahn YH, Choi HJ, Kang HG, Cheong HI, Ha IS. Measurement of Fluid Status Using Bioimpedance Methods in Korean Pediatric Patients on Hemodialysis. J Korean Med Sci. 2017;32(11):1828\u201334. PMID: 28960036; PMCID: PMC5639064.","journal-title":"J Korean Med Sci"},{"key":"5873_CR25","doi-asserted-by":"publisher","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitorsreduceheartfailurehospitalization? DiabetesObesMetab. 2018;20(3):479\u201387. https:\/\/doi.org\/10.1111\/dom.13126.","DOI":"10.1111\/dom.13126"},{"issue":"6","key":"5873_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of Empagliflozin on LeftVentricularVolumes. Circulation. 2021;143(6):516\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052186.","journal-title":"Circulation"},{"issue":"3","key":"5873_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. Empagliflozin in patientshospitalizedforacuteheartfailure. NatMed. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"NatMed"},{"key":"5873_CR28","doi-asserted-by":"publisher","first-page":"112606","DOI":"10.1016\/j.biopha.2021.112606","volume":"146","author":"S Zeng","year":"2022","unstructured":"Zeng S, Delic D, Chu C, Xiong Y, Luo T, Chen X, Gaballa MMS, Xue Y, Chen X, Cao Y, Hasan AA, Stadermann K, Frankenreiter S, Yin L, Kr\u00e4mer BK, Klein T, Hocher B. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet. Biomed Pharmacother. 2022;146:112606. https:\/\/doi.org\/10.1016\/j.biopha.2021.112606. Epub 2021 Dec 28. PMID: 34968924.","journal-title":"Biomed Pharmacother"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05873-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05873-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05873-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:38:56Z","timestamp":1781231936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05873-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5873"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05873-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Kayseri City Training and Research Hospital (Approval No: 732; Date: November 8, 2022). The study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with Good Clinical Practice (GCP) guidelines. Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}